XNAS · Healthcare · Biotechnology
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.23 | -0.18 | +21.74% | $6.6M | ✅ Beat | -0.55% | +8.01% | — |
| 2026-05-12 | Q1 2026 | -0.25 | -0.20 | +20.00% | $6.2M | ✅ Beat | -2.21% | -1.89% | +22.08% |
| 2026-02-26 |
| Q4 2025 |
| -0.41 |
| -0.18 |
| +56.10% |
| $11.0M |
| ✅ Beat |
| +0.00% |
| +8.99% |
| -13.31% |
| 2025-11-06 | Q3 2025 | -0.42 | -0.44 | -4.76% | $11.2M | ❌ Miss | — | — | — |
| 2025-08-07 | Q2 2025 | -0.38 | -0.37 | +2.63% | $6.5M | ✅ Beat | +3.57% | -8.91% | +5.43% |
| 2025-05-07 | Q1 2025 | -0.42 | -0.37 | +11.90% | $7.2M | ✅ Beat | — | — | — |
| 2025-02-27 | Q4 2024 | -0.37 | -0.49 | -32.43% | $5.2M | ❌ Miss | — | — | — |
| 2024-10-31 | Q3 2024 | -0.38 | -0.35 | +7.89% | $15.4M | ✅ Beat | — | — | — |
Showing last 8 quarters.